This paper examines the postwar rise of drug scientific marketing, i.e., the systematic mobilization of the biomedical sciences for promotion purposes as well as the rise of marketing into a form of science, taking the case of the German firm Schering. To analyze the specific articulation between in-house research, marketing practices and drug prescription the article follows the case of Schering's corticoids: cortisone in the 1950s, its derivatives in the 1960s. The contrasted promotional campaigns Schering organized for both of these products reveals the combined reorganization of promotional and in-house research activities, which took place at Schering after 1945, providing for new and more intimate relationship between science and the construction of markets. It also shows that this was a gradual process of change rather than a radical departure.